Changeflow GovPing Healthcare & Life Sciences Anticholinergic Agents Patent US12606549B2, Rez...
Routine Rule Added Final

Anticholinergic Agents Patent US12606549B2, Rezubio Pharma

Favicon for changeflow.com USPTO Patent Grants - Organic Chemistry (C07D)
Published
Detected
Email

Summary

The USPTO granted US Patent 12606549B2 to Rezubio Pharmaceuticals Co., Ltd covering muscarinic acetylcholine receptor antagonist compounds (including M3 antagonists) and pharmaceutical compositions for treating hyperhidrosis. The patent contains 19 claims and names Yusheng Xiong and Hongping Guan as inventors.

Published by USPTO on changeflow.com . Detected, standardized, and enriched by GovPing. Review our methodology and editorial standards .

What changed

Rezubio Pharmaceuticals Co., Ltd received US Patent 12606549B2 from the USPTO, covering anticholinergic compounds acting as muscarinic acetylcholine receptor antagonists (particularly M3 antagonists) and related pharmaceutical compositions. The patent, granted April 21, 2026, is based on Application No. 18254405 filed November 24, 2021.

Pharmaceutical companies developing treatments for hyperhidrosis or other conditions treatable by muscarinic receptor antagonism should evaluate this patent as potential prior art. Competitors pursuing similar M3 antagonist compounds may need to assess freedom to operate or consider licensing discussions with Rezubio Pharmaceuticals.

Archived snapshot

Apr 21, 2026

GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.

← USPTO Patent Grants

Anticholinergic agents

Grant US12606549B2 Kind: B2 Apr 21, 2026

Assignee

REZUBIO PHARMACEUTICALS CO., LTD

Inventors

Yusheng Xiong, Hongping Guan

Abstract

Compounds shown in Formula (I), pharmaceutical compositions, and methods of using related to muscarinic acetylcholine receptors. The compounds herein are typically muscarinic acetylcholine receptor antagonists, such as M3 antagonists, which can be used for treating a variety of disorders, conditions or diseases such as hyperhidrosis.

CPC Classifications

C07D 413/12 C07D 207/08 C07D 207/12

Filing Date

2021-11-24

Application No.

18254405

Claims

19

View original document →

Get daily alerts for USPTO Patent Grants - Organic Chemistry (C07D)

Daily digest delivered to your inbox.

Free. Unsubscribe anytime.

About this page

What is GovPing?

Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission

What's from the agency?

Source document text, dates, docket IDs, and authority are extracted directly from USPTO.

What's AI-generated?

The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.

Last updated

Classification

Agency
USPTO
Published
April 21st, 2026
Instrument
Rule
Branch
Executive
Legal weight
Binding
Stage
Final
Change scope
Substantive

Who this affects

Applies to
Pharmaceutical companies Drug manufacturers
Industry sector
3254 Pharmaceutical Manufacturing
Activity scope
Patent grant Drug compound IP M3 antagonist therapy
Geographic scope
United States US

Taxonomy

Primary area
Intellectual Property
Operational domain
Legal
Topics
Pharmaceuticals Healthcare

Get alerts for this source

We'll email you when USPTO Patent Grants - Organic Chemistry (C07D) publishes new changes.

Free. Unsubscribe anytime.

You're subscribed!